Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

4.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

24.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

129
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
129

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.

Cancer chemotherapy and pharmacology·2026
Same author

A Greek Case-Control Replication Study of <i>IKZF1</i> rs4132601 and <i>CDKN2A</i> rs3731217 in Childhood Acute Lymphoblastic Leukemia.

Genes·2026
Same author

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

Dermatology and therapy·2026
Same author

High-dose methotrexate toxicokinetic variability persists despite standardized 24-hour infusion in childhood ALL.

Cancer chemotherapy and pharmacology·2026
Same author

Results from TRIUMPH [EUROPE], a Real-World Observational Study on the 3-Month Effectiveness of Galcanezumab Versus Traditional Oral Migraine Preventive Medications.

Pain and therapy·2026
Same author

Targeting Telomerase in Cancer: Vaccine-Based Strategies, Clinical Evidence, and Synergy with Immunotherapy.

Diseases (Basel, Switzerland)·2026

Related Experiment Video

Updated: Apr 16, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.1K

miRNA-Processing Gene Variants and Neuroblastoma Susceptibility: A Pilot Case-Control Study.

Ioannis Kyriakidis1, Iordanis Pelagiadis1, Georgia Martimianaki1

  • 1Department of Pediatric Hematology-Oncology and Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion and Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, Heraklion, GRC.

Cureus
|April 15, 2026
PubMed
Summary

Genetic variants in microRNA processing genes may influence neuroblastoma susceptibility. Specifically, a DROSHA SNP showed a significant association in a Greek pediatric population, warranting further investigation.

Keywords:
argonautedicerdroshagenetic susceptibilitymicrornaneuroblastomapolymorphism

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.3K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

Related Experiment Videos

Last Updated: Apr 16, 2026

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.1K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.3K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Neuroblastoma (NB) is a common childhood cancer.
  • Inherited factors influencing NB susceptibility are not fully understood.
  • Defective microRNA (miRNA) biogenesis is linked to aggressive NB, suggesting germline variants in miRNA-processing genes as potential modifiers.

Purpose of the Study:

  • To investigate the association between selected single nucleotide polymorphisms (SNPs) in key miRNA-processing genes (DICER1, DROSHA, AGO1) and neuroblastoma susceptibility.
  • To assess these associations in a Greek pediatric population.

Main Methods:

  • Pilot case-control study involving 200 children (25 NB cases, 175 controls) from Crete, Greece.
  • Genotyping of five SNPs in DICER1, DROSHA, and AGO1 using TaqMan assays.
  • Logistic regression analyses adjusted for age and sex, with Bonferroni and false discovery rate (FDR) corrections for multiple testing.

Main Results:

  • The DROSHA rs3805500 SNP showed the strongest association with NB susceptibility (per G allele OR 3.43), remaining significant after multiple testing corrections.
  • DROSHA rs642321 had a nominal association, and DICER1 rs3742330 showed a borderline association, neither retaining significance after corrections.
  • No significant associations were found for AGO1 rs636832 or DROSHA rs10035440.

Conclusions:

  • Genetic variations in the miRNA-processing pathway may influence neuroblastoma susceptibility.
  • This pilot study suggests DROSHA rs3805500 as a potential genetic modifier.
  • Larger, ethnically diverse cohorts and functional studies are needed for clinical validation.